Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

5.69
-0.0800-1.39%
Pre-market: 5.740.0500+0.88%04:24 EDT
Volume:2.06M
Turnover:11.65M
Market Cap:1.85B
PE:-13.79
High:5.78
Open:5.70
Low:5.54
Close:5.77
52wk High:7.30
52wk Low:2.71
Shares:325.83M
Float Shares:233.00M
Volume Ratio:1.05
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4126
EPS(LYR):-0.3409
ROE:-47.05%
ROA:-23.82%
PB:4.79
PE(LYR):-16.69

Loading ...

Taysha Gene Therapies Highlights TSHA-102 Rett Gene Therapy Path Toward BLA Submission in Corporate Presentation

Reuters
·
15 hours ago

MeiraGTx Q2 Revenue Jumps on Reogen License Revenue

Reuters
·
Aug 13

Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations

Reuters
·
Aug 13

Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return

Simply Wall St.
·
Aug 13

Turn Therapeutics Q2 Net Loss Per Share Widens on Higher R&D Costs

Reuters
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

TIPRANKS
·
Aug 12

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 12

Taysha Falls on Wider-than-Expected Quarterly Loss

Reuters
·
Aug 12

Piper Sandler Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

TIPRANKS
·
Aug 12

Taysha Gene Therapies, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Taysha Gene Therapies Q2 Loss Widens

MT Newswires Live
·
Aug 12

Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss

MT Newswires Live
·
Aug 12

Taysha Gene Therapies Q2 Net Income USD -46.639 Million

Reuters
·
Aug 12

Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate

Benzinga Earnings
·
Aug 12

Taysha Gene Therapies Rugi Bersih Q2 FY26 Melebar Ke USD 46,64 Juta; Belanja R&D Naik 92,11% Menjadi USD 38,64 Juta

Reuters
·
Aug 12

Taysha Gene Therapies Q2 Operating Expenses USD 47.349 Million

THOMSON REUTERS
·
Aug 12

Taysha Gene Therapies Q2 EPS USD -0.13

THOMSON REUTERS
·
Aug 12

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 12

Taysha Gene Therapies Grants New Hire 144,000 RSUs, 92,400 Stock Options Priced at $5.78

Reuters
·
Aug 07